Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Moodys
Baxter
Merck
McKesson

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMPHETAMINE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

505(b)(2) Clinical Trials for Amphetamine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Indication NCT01189214 Psychopharmacotherapy in Multiple Substances Abuse Completed National Institutes of Health (NIH) Phase 3 2009-03-01 Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
New Indication NCT01189214 Psychopharmacotherapy in Multiple Substances Abuse Completed National Cheng-Kung University Hospital Phase 3 2009-03-01 Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
OTC NCT01736332 Factors Affecting Methamphetamine and Opiates Drug Testing Completed National Institute on Drug Abuse (NIDA) Phase 1 2012-07-01 Background: - Some legal over-the-counter drugs (such as Vicks VapoInhaler ) and some foods (such as poppy seeds) may cause a positive screening drug test. This might look like someone used illegal drugs (such as methamphetamines or opiates) when they did not. Researchers are studying how the body handles chemicals that may test like illegal drugs and for how long they may be detected in the body. Blood, saliva, and urine samples will be collected. This study may help improve the effectiveness and accuracy of drug tests. Objectives: - To see how the body handles chemicals that may produce positive screening tests and how additional testing can eliminate positive drug tests from over-the-counter drugs and food. Eligibility: - Healthy volunteers between 18 and 65 years of age. Design: - Participants are screened with a physical exam, medical history, laboratory tests, and ECG. - This study involves an overnight stay on a secure research unit and 2 days of tests. - On the first day, participants will take Vicks VapoInhaler (two inhalations in each nostril) every 2 hours from 9 a.m. to 7 p.m. They will also take a drink containing poppy seeds twice (at about 9 a.m. and 5 p.m.). - On the morning of the second day, participants will take the Vicks VapoInhaler just once. They will be discharged around 5 p.m. - On both days, participants will provide blood and saliva samples several times throughout the day. All of their urine will be collected during the 2 study days.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Amphetamine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000305 Amphetamine Cocaine Interaction Study - 2 Terminated National Institute on Drug Abuse (NIDA) Phase 1 1969-12-31 The purpose of this study is to evaluate results of d-amphetamine - cocaine (pharmacology) interaction study.
NCT00000305 Amphetamine Cocaine Interaction Study - 2 Terminated University of Texas Phase 1 1969-12-31 The purpose of this study is to evaluate results of d-amphetamine - cocaine (pharmacology) interaction study.
NCT00000305 Amphetamine Cocaine Interaction Study - 2 Terminated The University of Texas Health Science Center, Houston Phase 1 1969-12-31 The purpose of this study is to evaluate results of d-amphetamine - cocaine (pharmacology) interaction study.
NCT00000308 Dextroamphetamine-Cocaine Behavioral Intervention - 5 Completed University of Texas Phase 2 1995-09-01 The purpose of this study is to examine dextroamphetamine-cocaine behavioral intervention in cocaine dependent patients.
NCT00000308 Dextroamphetamine-Cocaine Behavioral Intervention - 5 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-09-01 The purpose of this study is to examine dextroamphetamine-cocaine behavioral intervention in cocaine dependent patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amphetamine

Condition Name

Condition Name for Amphetamine
Intervention Trials
Attention Deficit Hyperactivity Disorder 12
Healthy 11
Cocaine Dependence 9
Attention Deficit Disorder With Hyperactivity 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Amphetamine
Intervention Trials
Attention Deficit Disorder with Hyperactivity 35
Disease 28
Hyperkinesis 25
Cocaine-Related Disorders 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Amphetamine

Trials by Country

Trials by Country for Amphetamine
Location Trials
United States 111
Germany 12
Canada 9
France 6
Switzerland 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Amphetamine
Location Trials
California 14
Texas 14
New York 13
Florida 8
Maryland 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Amphetamine

Clinical Trial Phase

Clinical Trial Phase for Amphetamine
Clinical Trial Phase Trials
Phase 4 32
Phase 3 16
Phase 2/Phase 3 8
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Amphetamine
Clinical Trial Phase Trials
Completed 84
Recruiting 24
Not yet recruiting 18
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Amphetamine

Sponsor Name

Sponsor Name for Amphetamine
Sponsor Trials
National Institute on Drug Abuse (NIDA) 25
Shire 11
Yale University 9
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Amphetamine
Sponsor Trials
Other 155
Industry 40
NIH 37
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Mallinckrodt
McKesson
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.